Pyrazoleamide MAT2A Inhibitors for MTAP-Deficient Cancers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cancers such as Lung Adenocarcinoma, Melanoma, Pancreatic Adenocarcinoma, Head and Neck Squamous Cell Carcinoma, Lung Squamous Cell Carcinoma, Esophageal Carcinoma, Glioblastoma Multiforme, and Mesothelioma are limited by the inability to effectively target tumor suppressor genes like MTAP, which are frequently deleted in these cancers, leading to unmet medical needs and limited therapeutic options.
Innovation Solution
Development of pyrazoleamide derivatives that inhibit Human methionine adenosyltransferase 2A (MAT2A), a key enzyme in the methionine salvage pathway, to selectively target and inhibit cancer cells lacking MTAP, thereby disrupting their growth and survival.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current cancer treatments are used, then treatment coverage is provided, but efficacy is limited due to absence of direct inhibitors for mutant tumor suppressor proteins
Solution Approach 1:
The patent uses MAT2A as an intermediary target instead of directly targeting mutant tumor suppressor proteins. By inhibiting MAT2A, which is conditionally essential in MTAP-deficient cancer cells, the treatment achieves efficacy without needing to directly bind to or activate mutant proteins. This mediator approach resolves the contradiction by providing a reliable treatment mechanism that works around the inability to directly target mutant suppressor proteins.
2Reliability
If MTAP deletion is targeted, then conditional synthetic lethal relationship is exploited, but requires specific genetic definition of patient population
Solution Approach 1:
The patent applies local quality by targeting the specific metabolic vulnerability in MTAP-deficient cells rather than attempting a universal cancer treatment. The MAT2A inhibitor works specifically in cells with the MTAP deletion genetic alteration, exploiting the local metabolic defect in these cells. This resolves the contradiction by providing reliable therapeutic benefit for the specific genetic subgroup while accepting that the treatment is not universally applicable to all cancer types.
3Reliability
If MAT2A inhibition is implemented, then cancer progression is delayed, but requires potent and selective inhibitors to be developed
Solution Approach 1:
The patent employs parameter changes by optimizing the chemical structure of MAT2A inhibitors to achieve potent and selective inhibition. By modifying molecular parameters such as binding affinity, selectivity, and pharmacokinetic properties, the invention develops compounds that effectively delay cancer progression. This resolves the contradiction by systematically optimizing drug parameters to achieve the desired therapeutic effect while managing the complexity of inhibitor development.
Data Source
AI summary
The present invention provides compounds of formula I or II:wherein X1, R1 and R2 are as described herein, as well as pharmaceutically acceptable salts thereof. Further the present invention is concerned with the manufacture of the compounds of formula I, pharmaceutical compositions comprising them and their use as medicaments.